@article{a7bc11ec357b414bbac67e97062f9ff7,
title = "MAIA under the microscope — bringing trial design into focus",
abstract = "Using the example of the recently reported phase III MAIA trial, we emphasize herein the requirement to dig deeper into trial designs and end points to determine their appropriateness for the questions at hand and to assess whether a benefit in terms of the primary end point — even if statistically significant and seemingly clinically meaningful — is sufficient to warrant a change in clinical practice.",
author = "Prashant Kapoor and Rajkumar, {S. Vincent}",
note = "Funding Information: P.K. is the principal investigator of trials for which the Mayo Clinic receives research funding from Amgen, GlaxoSmithKline, Janssen, Sanofi and Takeda. S.V.R. declares no competing interests. Funding Information: The work of the authors is supported in part by grants CA107476, CA168762 and CA186781 from the US National Cancer Institute. Publisher Copyright: {\textcopyright} 2019, Springer Nature Limited. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2019",
month = jun,
day = "1",
doi = "10.1038/s41571-019-0198-0",
language = "English (US)",
volume = "16",
pages = "339--340",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "6",
}